Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for CMV Prophylaxis After CAR-T Therapy
NCT06575374Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2024
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of letermovir in cytomegalovirus infection (CMV), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2024; status: recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06575374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06575374.